Is STEM a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,256 people get STEM articles and Market Currents by email alert.

Get email alerts on STEM »

HEADLINES:

Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 4 Comments
StemCells Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
StemCells, Inc. Reports First Quarter 2013 Financial Results and Provides Business Update

GlobeNewswire (May 9, 2013)
StemCells, Inc. Announces Webcast to Discuss First Quarter 2013 Financial Results and Business Update

GlobeNewswire (May 7, 2013)
StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Company
BlackbirdAnalytics • Thu, May 2 • 13 Comments
StemCells, Inc. Adds Byers Eye Institute at Stanford as Second Site for Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration

GlobeNewswire (Apr 18, 2013)
Investing In The Stem Cell Sector: An Overview
EnhydrisPECorp • Wed, Apr 17 • 25 Comments
StemCells, Inc. to Participate at 2013 Regen Med Investor Day in New York

GlobeNewswire (Apr 15, 2013)
StemCells, Inc. Enters Agreement to Receive $19.3 Million From California Institute for Regenerative Medicine to Help Fund IND for Alzheimer's Disease

GlobeNewswire (Apr 11, 2013)
The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy
Brian Nichols • Wed, Apr 10 • 28 Comments
CORRECTION -- StemCells, Inc. Closes $10 Million Debt Financing

GlobeNewswire (Apr 9, 2013)
StemCells, Inc. Closes $10 Million Debt Financing

GlobeNewswire (Apr 9, 2013)
Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy
Bioassociate Consulting • Thu, Mar 28 • 5 Comments
StemCells Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 21
StemCells, Inc. Expands Patent Portfolio

GlobeNewswire (Mar 20, 2013)
Phase II Trials Will Be Pivotal For These Stem Cell Companies
Ryan's View • Wed, Mar 20 • 11 Comments
StemCells, Inc. Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Business Update

GlobeNewswire (Mar 19, 2013)
StemCells' Recent Share Price Drop
WM Analyst • Mon, Mar 4 • 7 Comments
StemCells, Inc. Announces First Patient Cohort Completes Spinal Cord Injury Trial - Gains in Sensory Function Persist 12 Months After Stem Cell Transplant

GlobeNewswire (Feb 12, 2013)
StemCells, Inc. to Present at 2013 BIO CEO & Investor Conference

GlobeNewswire (Feb 6, 2013)

To learn more about Seeking Alpha Pro, click here.

StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Company
BlackbirdAnalytics • Thu, May 2 • 13 Comments
StemCells' Recent Share Price Drop
WM Analyst • Mon, Mar 4 • 7 Comments
StemCells' Recent Decline Offers New Entry Point For Investors
Chris Katje • Tue, Aug 7, 2012 • 3 Comments
StemCells Huge Tuesday Gain Is Only The Beginning In 2012
Chris Katje • Tue, Jul 17, 2012 • 15 Comments
StemCells Q3 2011 Earnings
Henry McCusker • Mon, Nov 7, 2011
Global Factors Boosting Biotech Today
Research Recap • Tue, Aug 24, 2010
StemCells Inc. Transplant Patient Heads Home
H.S. Ayoub • Tue, Dec 12, 2006 • 1 Comment

Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 4 Comments
Investing In The Stem Cell Sector: An Overview
EnhydrisPECorp • Wed, Apr 17 • 25 Comments
The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy
Brian Nichols • Wed, Apr 10 • 28 Comments
Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy
Bioassociate Consulting • Thu, Mar 28 • 5 Comments
Phase II Trials Will Be Pivotal For These Stem Cell Companies
Ryan's View • Wed, Mar 20 • 11 Comments
Stem Cell Therapy Companies: Underappreciated Outperformers
Ryan's View • Tue, Jan 29 • 11 Comments
Stem Cell Stocks To Consider: Aastrom, Athersys, StemCells And Neuralstem
BuySellShort • Wed, Jan 16 • 6 Comments
The Race To Cure Spinal Cord Injuries
PropThink • Tue, Jan 15 • 33 Comments
Stem Cell Companies For Consideration In 2013
The Swiss Trader • Wed, Jan 9 • 30 Comments
Stem Cells, Dr. Oz And A Potentially Lucrative Investment Opportunity
Charles Moscoe • Wed, Jan 2 • 32 Comments
Stem Cell Technology To Revolutionize The Skin Care Industry?
Charles Moscoe • Tue, Dec 18, 2012 • 5 Comments
Maxim Group Highlights 3 Stem Cell Stocks To Consider And 1 To Avoid
Ben Yoffe • Tue, Dec 4, 2012 • 36 Comments
An Exciting Week In Cell Therapy
The Swiss Trader • Mon, Nov 12, 2012 • 13 Comments
NeoStem to Create Value with Billion Dollar Potential
Amy Baldwin • Wed, Nov 7, 2012 • 35 Comments
Neuralstem Swinging For The ALS Fences
Richard Richter • Mon, Oct 29, 2012 • 5 Comments
The Figure-4 Dead Fall Trap And 4-Biotechnology Recommendations For October
Michael Webb • Thu, Oct 18, 2012 • 24 Comments
Nobel Prize Validates Recent Stem Cell Headlines
Brian Nichols • Tue, Oct 16, 2012 • 26 Comments
Savient Pharmaceuticals May Continue To Run Higher
Scott Matusow • Tue, Oct 9, 2012 • 7 Comments
5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments
Scott Matusow • Tue, Oct 9, 2012 • 14 Comments
NeoStem: The Best Upside In An Innovating Space
Henry Kawabe • Sun, Oct 7, 2012 • 25 Comments

StemCells Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
StemCells Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 21
StemCells' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 9, 2012 • 1 Comment
StemCells, Inc. CEO Discusses Interim 6-Month Data From Spinal Cord Injury Trial - Call Transcript
Tue, Sep 4, 2012 • 1 Comment
StemCells' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Mon, Aug 6, 2012

StemCells, Inc. Reports First Quarter 2013 Financial Results and Provides Business Update

GlobeNewswire (May 9, 2013)
StemCells, Inc. Announces Webcast to Discuss First Quarter 2013 Financial Results and Business Update

GlobeNewswire (May 7, 2013)
StemCells, Inc. Adds Byers Eye Institute at Stanford as Second Site for Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration

GlobeNewswire (Apr 18, 2013)
StemCells, Inc. to Participate at 2013 Regen Med Investor Day in New York

GlobeNewswire (Apr 15, 2013)
StemCells, Inc. Enters Agreement to Receive $19.3 Million From California Institute for Regenerative Medicine to Help Fund IND for Alzheimer's Disease

GlobeNewswire (Apr 11, 2013)
CORRECTION -- StemCells, Inc. Closes $10 Million Debt Financing

GlobeNewswire (Apr 9, 2013)
StemCells, Inc. Closes $10 Million Debt Financing

GlobeNewswire (Apr 9, 2013)
StemCells, Inc. Expands Patent Portfolio

GlobeNewswire (Mar 20, 2013)
StemCells, Inc. Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Business Update

GlobeNewswire (Mar 19, 2013)
Movers & Shakers: Tuesday’s biggest gaining and declining stocks

at MarketWatch.com (Feb 12, 2013)
StemCells, Inc. Announces First Patient Cohort Completes Spinal Cord Injury Trial - Gains in Sensory Function Persist 12 Months After Stem Cell Transplant

GlobeNewswire (Feb 12, 2013)
StemCells, Inc. to Present at 2013 BIO CEO & Investor Conference

GlobeNewswire (Feb 6, 2013)
StemCells, Inc. to Present at Phacilitate Cell & Gene Therapy Forum

GlobeNewswire (Jan 23, 2013)
StemCells, Inc. to Present at 2012 World Stem Cell Summit

GlobeNewswire (Nov 29, 2012)
StemCells, Inc. Reports Third Quarter 2012 Financial Results and Provides Business Update

GlobeNewswire (Nov 8, 2012)
StemCells, Inc. Announces Webcast to Discuss Third Quarter 2012 Financial Results and Business Update

GlobeNewswire (Nov 5, 2012)
StemCells, Inc. Partners With R Biomedical to Develop and Commercialize Reagents for Human iPS Cell Research

GlobeNewswire (Oct 30, 2012)
StemCells, Inc. to Present at 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum

GlobeNewswire (Oct 26, 2012)
StemCells, Inc. Adds Eliseo Salinas to Advise on Product Development Strategy for Its Proprietary Human Neural Stem Cells

GlobeNewswire (Oct 18, 2012)
Ascendiant Capital Markets Initiates Research Coverage of StemCells, Inc. With Buy Recommendation

GlobeNewswire (Oct 17, 2012)

STEM vs. ETF Alternatives

Company Description

StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. We believe that understanding cells and cell biology, and in particular stem cells, will play an increasingly important role in... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 23, 10:36 AM Shares of Stemline Therapeutics (STML -2.2%) slip this morning after Jefferies and Aegis Capital announced an exercise of their option to purchase around 620K additional shares in connection with STEM's previously announced 4.1M share public offering. The option's exercise at $14.50 per share will add around $69M in total gross proceeds to STEM's coffers before deducting underwriting discounts and commissions. Closing is expected on or about May 28. Comment! [Healthcare, On the Move]
Thursday, May 16, 10:46 AM Shares of stem cell research firms are rallying today on the back of an announcement today by the Oregon Health and Science University that they've successfully reproduced human stem cells by cloning. Cloning stem cells in this fashion could lead to cell therapies using a patient’s own cells and thereby avoid the problems of immune suppression: StemCells (STEM +2.2%), NeuralStem (CUR +2.1%), NeoStem (NBS +2.2%). Comment! [Healthcare, On the Move]
Thursday, May 9, 5:14 PM StemCells (STEM): Q1 EPS of -$0.17 misses by $0.04. Revenue of $284K misses by $6K. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Thursday, April 11, 9:35 AM StemCells (STEM) jumps 11.2% after saying that it's entered into an agreement to receive a "forgivable loan" of $19.3M from the California Institute for Regenerative Medicine to help finance the development of the company's HuCNS-SC treatment for Alzheimer's Disease and fund FDA filings. Repayment of the loan is contingent on the success of HuCNS-SC cells in Alzheimer's disease. (PR) Comment! [Healthcare, On the Move]
Thursday, April 11, 9:10 AM Premarket gainers: ACAD +43%. AMRS +15%. STEM +12%. RAD +12%. AEZS +11%. BYD +7%. BDSI +6%.
Losers: FTNT -18%. AFFY -10%. SGYP -10%. HPQ -6%. Comment! [On the Move]
Tuesday, April 9, 9:49 AM StemCells (STEM +2.8% to $1.66) closes $10M in debt financing from Silicon Valley Bank (SVB), which will increase the company's December 31, 2013 pro forma cash balance to $34.4M. StemCells also issues SVB a 10-year warrant to acquire 293,531 shares at $1.7034 each. (PR) Comment! [Healthcare]
Wednesday, March 20, 2:27 PM StemCells (STEM -0.6%) says it's acquired a patent family claiming GFAP+ Nestin+ cells from NsGene A/S, a privately held Danish biotechnology company. The patents extend into 2020 and 2021, respectively. GFAP and Nestin are proteins that are co-expressed by certain key cells found in the human central nervous system, and were the result of NsGene's Parkinson's disease research. Comment! [Healthcare]
Tuesday, March 19, 12:16 PM StemCells (STEM -3.9%) slips after reporting a Q4 loss of $0.07 per share, beating the Street consensus of $0.13 loss per share. Revenues were far short of estimates, coming in at $211K, versus analyst estimates of $330K and far below the prior year's $541K. The company attributes the decline to higher revenue from licensing agreements in 2011. Comment! [Healthcare, On the Move, Earnings]
Tuesday, March 19, 9:14 AM StemCells (STEM): Q4 EPS of -$0.07 beats by $0.07. Revenue of $211K misses by $99K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 12, 12:45 PM Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move]
Tuesday, February 12, 9:10 AM Premarket gainers: STEM +30%. ZIOP +14%. KORS +12%. MAS +8%. AVP +7%. HERO +7%. BCS +7%. GY +6%. OPXA +6%. GTE +5%.
Losers: MELA -17%. ORIG -5%. WNS -5%.
Comment! [On the Move]
Tuesday, February 12, 8:27 AM StemCells (STEM) jumps 26% after saying that its HuCNS-SC product for for chronic spinal cord injury continued to perform well after 12 months of a Phase I/II trial of three patients. The sensory gains that two out of the patients achieved after six months have persisted, with one even converting from a "complete" to an "incomplete injury." Comment! [Healthcare, On the Move]
Tuesday, January 22, 3:40 PM Athersys (ATHX +6.4%) gets a boost today, possibly from an upbeat Seeking Alpha piece that touts its strong pipeline. ATHX is a clinical stage biopharmaceutical company with a number of potential catalysts in its portfolio. Its most advanced programs are in the area of regenerative medicine using its stem cell therapy called MultiStem for the treatment of ischemic stroke. StemCells (STEM -2.3%) slips, possibly on the same article, which says it's in pre-clinical trials for the same indication, but its product isn't as advanced as that of ATHX. 1 Comment [Healthcare, On the Move]
Friday, November 9, 2012, 11:00 AM StemCells (STEM -6.1%) takes a hit after its Q3 came up far short of estimates yesterday. The company reported a $0.54 loss for the period, missing Street estimates for a loss of $0.17. Revenue was also behind the curve, coming in at $264K, versus analysts expectations of $430K. Other expenses for the quarter weighed on bottom-line results, largely due to a non-cash expense from an increase in the estimated fair value of its warrant liability. Comment! [Healthcare, On the Move, Earnings]
Tuesday, October 30, 2012, 9:40 AM StemCells (STEM) partners with Edinburgh, UK-based R Biomedical to develop and commercialize a range of cell lines and reagents to be used in stem cell-based research for regenerative medicine applications. The first product under the partnership, an "ultra-primary" human fibroblast cell line from which researchers can generate iPS cell lines, was launched today under STEM's SC Proven brand. Comment! [Healthcare]
Wednesday, October 17, 2012, 10:11 AM Ascendiant Capital Markets initiates coverage on StemCells (STEM +1.7% to $2.44) with a "Buy" recommendation and a price target of $2.60. "We believe that StemCells is an intriguing speculative small cap investment story," Ascendiant writes. "The Company is breaking new ground in its development of novel stem cell therapies." Comment! [Healthcare, Quick Ideas]

lazertron
In $ACAD and $STEM. A nice start in the trading day. Also $SNWV received a patent on blood sterlisation using their Shock Wave technology.
Apr 11, 9:32 AM
Reply (5)

• !Report Abuse
View all 5 replies
lazertron: my car ;) Porsche GT3 RS
Apr 11, 10:51 AM
• !Report Abuse
wheelz23: holy ACAD!!!!!
Apr 11, 2:49 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

IALF
STEM always seems to pop when it sits around 2.00. Remind me why I don't start a position?
10/4/12
Reply (3)

• !Report Abuse
View all 3 replies
Noreika: lol
10/4/12
• !Report Abuse
Noreika: I miss that show
10/4/12
• !Report Abuse
Add a reply...

140 characters

The_American
BIIB CELG AMGN BMY LLY PFE MRK GILD looking into STEM Cells IMMU CTIC as revolutionary Science and Technology they should be acquiring ESRX
10/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Robbster
CUR, PSTI, STEM all making steady progress in their respective stages of development. IMUC is in buy range. Biotechs with real results +1
9/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Robbster
My picks for my persona "Breakthrough Biotech Fund": PSTI, IMUC, (incumbents) GALE, NLNK, STEM (new additions). Up big on incumbents...
9/10/12
Reply (5)

• !Report Abuse
View all 5 replies
Robbster: PSTI has high expectations of revenue growth due to breakthrough disease treatments so incremental offering only suppressed price short term
9/20/12
• !Report Abuse
Robbster: So, even though each PSTI share now represents a lower percentage of the company, folks believe proceeds will be used to grow company faster
9/20/12
• !Report Abuse
Add a reply...

140 characters

Stickmanwithahaircut
STEM up 20% premarket ? Restored sensation in spinal cord patients.
9/4/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Droney
(STEM) StemCells, Inc. Reports Positive Interim Data From Spinal Cord Injury Trial. http://bit.ly/Up6uVk
9/4/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

phemale60
STEM looks like taking off - any substance?
8/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Victoria70
What happened to STEM gang? I thought for sure we were making higher highs each day. Hit my 10% stop loss. This stinks...
7/26/12
Reply (1)

• !Report Abuse
View all 1 replies
Juuso E: The alzheimer news could only fuel new highs for so long, its just giving back some.
7/26/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

lazertron
In $ACAD and $STEM. A nice start in the trading day. Also $SNWV received a patent on blood sterlisation using their Shock Wave technology.
Apr 11, 9:32 AM
Reply (5)

• !Report Abuse
View all 5 replies
lazertron: my car ;) Porsche GT3 RS
Apr 11, 10:51 AM
• !Report Abuse
wheelz23: holy ACAD!!!!!
Apr 11, 2:49 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

IALF
STEM always seems to pop when it sits around 2.00. Remind me why I don't start a position?
10/4/12
Reply (3)

• !Report Abuse
View all 3 replies
Noreika: lol
10/4/12
• !Report Abuse
Noreika: I miss that show
10/4/12
• !Report Abuse
Add a reply...

140 characters

Robbster
My picks for my persona "Breakthrough Biotech Fund": PSTI, IMUC, (incumbents) GALE, NLNK, STEM (new additions). Up big on incumbents...
9/10/12
Reply (5)

• !Report Abuse
View all 5 replies
Robbster: PSTI has high expectations of revenue growth due to breakthrough disease treatments so incremental offering only suppressed price short term
9/20/12
• !Report Abuse
Robbster: So, even though each PSTI share now represents a lower percentage of the company, folks believe proceeds will be used to grow company faster
9/20/12
• !Report Abuse
Add a reply...

140 characters

Juuso E
I'd like to know what STEM was doing in the 90s and early 2000s, neither Yahoo nor Google have any articles dating back to that time...
7/24/12
Reply (4)

• !Report Abuse
View all 4 replies
Stickmanwithahaircut: Yep. That's when it's a better gamble you know. Just ask the Perfessor what to do, LOL. I think it was $5-$10 then a dozen rev. splits ?!?!?
7/29/12
• !Report Abuse
Juuso E: Probably
7/29/12
• !Report Abuse
Add a reply...

140 characters

Victoria70
What happened to STEM gang? I thought for sure we were making higher highs each day. Hit my 10% stop loss. This stinks...
7/26/12
Reply (1)

• !Report Abuse
View all 1 replies
Juuso E: The alzheimer news could only fuel new highs for so long, its just giving back some.
7/26/12
• !Report Abuse
Add a reply...

140 characters

Stickmanwithahaircut
STEM is up 44% after it's Alzheimer's study results are released. Study shows rebuilt neural brain cells improve memory. Whahoo!
7/17/12
Reply (7)

• !Report Abuse
View all 7 replies
skywola: Got me, I normally trade only pharmaceutical stocks! Buy at bottom, wait for ride to top . . . As with STEM. Did it before with GALE too.
7/17/12
• !Report Abuse
Stickmanwithahaircut: It's been a long while since so many owners have bought up their own outstanding shares as has happened in the last few weeks.
7/22/12
• !Report Abuse
Add a reply...

140 characters

The_American
GSK DNDN TNGN.OB CTIC STEM should ALL be looked at into the BIB space and PFE MRK GSK should be looking into much more MDT also looking AMRS X
4/21/12
Reply (6)

• !Report Abuse
View all 6 replies
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
Add a reply...

140 characters

STEM StemCells, Inc.

STEM

StemCells, Inc.